MOLECULAR PARTNERS AG
MOLN evidence brief
What we can confirm
- Market Cap:
- $153.2M
What it means
What to watch
Prepared research question
What matters most for MOLN—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · MOLN
Molecular Partners AG is a clinical-stage biotechnology company developing DARPin-based therapeutics, primarily for oncology, with a focus on Radio-DARPins and T-cell engagers.
Key risk: Clinical-stage risk
Market Cap
$153.2M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Tracking 3 clinical trials for MOLECULAR PARTNERS AG.
Molecular Partners AG is a clinical-stage biotechnology company developing DARPin-based therapeutics, primarily for oncology, with a focus on Radio-DARPins and T-cell engagers.
- Molecular Partners is a clinical-stage biotechnology company pioneering DARPin therapeutics for medical challenges other modalities cannot readily address [sec · filed 2026-03-12].
- The company's lead programs include MP0712 (a 212Pb-based Radio-DARPin targeting DLL3 for SCLC) and MP0533 (a tetra-specific T-cell engager for AML) [sec · filed 2026-03-12].
- In H1 2025, the company reduced its workforce by up to 40 positions (~24%) to extend cash runway into 2028 [sec · filed 2025-08-25].
- The company anticipates increasing expenses as it initiates new clinical trials and continues existing ones, which may lead to continued losses [sec · filed 2026-03-12].
- Molecular Partners has a global partnership with Orano Med for its Radio-DARPin pipeline [sec · filed 2025-08-25].
What works
- Proprietary DARPin platform offers unique properties (small size, high affinity, multispecificity) that may address limitations of antibodies and small molecules [sec · filed 2026-03-12].
- Radio-DARPin technology with half-life engineering has shown improved tumor uptake and reduced kidney reabsorption, supporting pipeline expansion [sec · filed 2026-03-12].
- Cash runway extended into 2028 following strategic workforce reduction, providing financial stability for ongoing programs [sec · filed 2025-08-25].
- Strong leadership with appointment of Martin Steegmaier, Ph.D., as CSO [sec · filed 2025-08-25].
What to weigh
- The company has incurred losses and expects continued losses as it advances clinical trials, reducing working capital and shareholders' equity [sec · filed 2026-03-12].
- Workforce reduction of up to 40 positions (~24%) indicates organizational restructuring and potential operational constraints [sec · filed 2025-08-25].
- Dependence on early-stage clinical programs (Phase 1/2a) means no approved products and high regulatory and execution risk [sec · filed 2026-03-12].
- Expenses are expected to increase substantially with new trial initiations, potentially straining resources [sec · filed 2026-03-12].
From the filings
Quoted directly from source documents.
DARPin platform differentiates from other modalities
“DARPins have several intrinsic properties that differentiate them from other modalities.”
SEC filings · March 12, 2026
Workforce reduction to extend cash runway
“the Company now anticipates its cash runway to extend into 2028, beyond its prior guidance of 2027.”
SEC filings · August 25, 2025
MP0712 is a lead Radio-DARPin program
“Our lead Radio-DARPin program MP0712, co”
SEC filings · March 12, 2026
Company expects continued losses
“may result in incurring losses in future periods.”
SEC filings · March 12, 2026
Risks & what to watch (3)›
Key risks
- Clinical-stage risk — All programs are in early clinical or preclinical stages; no approved products. [sec · filed 2026-03-12]
- Financial sustainability — Continued losses and increasing expenses may reduce working capital and shareholders' equity. [sec · filed 2026-03-12]
- Workforce reduction impact — Up to 24% workforce reduction may affect operational capacity and morale. [sec · filed 2025-08-25]
What to watch
- Initiation and progress of Phase 1 trial for MP0712 (Radio-DARPin) [sec · filed 2026-03-12].
- First data from amended Phase 1/2a trial of MP0533 expected Q4 2025 [sec · filed 2025-08-25].
- Expansion of MP0533 into combination studies and front-line AML [sec · filed 2026-03-12].
- Lead candidate selection for CD3 Switch-DARPin T cell engager program [sec · filed 2026-03-12].
Sources: SEC filings · Generated September 28, 2026 · How we verify sources →
Run MOLECULAR PARTNERS AG through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available MOLECULAR PARTNERS AG facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Regulatory
Financials
Short Interest
as of May 1, 2026- % of float
- 0.1%
- Days to cover
- 3.4
- Shares short
- 12,887
- Daily short volume (Aug 19, 2026)
- 0.9%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
MOLN short interestFrequently asked questions
What is the AI investment thesis for MOLECULAR PARTNERS AG?
Molecular Partners AG is a clinical-stage biotechnology company developing DARPin-based therapeutics, primarily for oncology, with a focus on Radio-DARPins and T-cell engagers.
Who is the CEO of MOLECULAR PARTNERS AG?
Dr. Patrick Amstutz Ph.D. is the chief executive officer of MOLECULAR PARTNERS AG (MOLN).
Where is MOLECULAR PARTNERS AG headquartered?
MOLECULAR PARTNERS AG (MOLN) is headquartered in Schlieren, Switzerland.
What therapeutic areas does MOLECULAR PARTNERS AG focus on?
MOLECULAR PARTNERS AG develops therapies across Oncology, Respiratory.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.